SCHEMBL7240514

SCHEMBL7240514

Cc1ccc(Sc2ccc(Nc3ncnc4cnc(NC(=O)C#CCCCCN5CCOCC5)cc34)cc2Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.67
ERBB2 P04626 17/20 0.67
ERBB4 Q15303 15/20 0.67
JAK3 P52333 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SRC P12931 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7237577 0.91 EGFR (0.73) EGFRERBB2ERBB4JAK3MEN1
SCHEMBL7214306 0.86 EGFR (0.90) EGFRERBB2ERBB4JAK3MEN1
SCHEMBL7221044 0.83 EGFR (0.91) EGFRERBB2ERBB4JAK3MEN1
SCHEMBL7220144 0.81 EGFR (1.00) EGFRERBB2ERBB4JAK3MEN1
SCHEMBL7233594 0.81 EGFR (0.67) EGFRERBB2ERBB4JAK3
SCHEMBL7214038 0.80 EGFR (0.71) EGFRERBB2ERBB4
SCHEMBL7236783 0.80 EGFR (0.65) EGFRERBB2ERBB4JAK3SRC
SCHEMBL7125757 0.79 EGFR (0.65) EGFRERBB2ERBB4JAK3
SCHEMBL7239963 0.79 EGFR (0.72) EGFRERBB2ERBB4JAK3MEN1
SCHEMBL7237640 0.78 EGFR (0.63) EGFRERBB2ERBB4JAK3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562818-B1 For treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis WARNER-LAMBERT COMPANY 2003-05-13 US claimed
US-6562818-B1 For treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis WARNER-LAMBERT COMPANY 2003-05-13 US disclosed
US-6127374-A AN ENZYME INHIBITOR FOR TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS AND PSORIASIS WARNER-LAMBERT COMPANY (US) 2000-10-03 US disclosed